title: Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate.
abstract: Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant Staphylococcus aureus (MRSA). Our case is unique in the description of an MRSA USA 300 isolate that developed decreased susceptibility to daptomycin during daptomycin and vancomycin therapy. Directed sequencing detected a previously reported mutation in mprF, resulting in a T345A substitution, associated with non-susceptibility to daptomycin.
authors.affiliation: Department of Internal Medicine and Infectious Disease, University of Nebraska Medical Center, Omaha, USA.
authors.forename: Madhukiran H
authors.initials: MH
authors.lastname: Murthy
authors.affiliation: Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Olson
authors.affiliation: Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
authors.forename: Robert W
authors.initials: RW
authors.lastname: Wickert
authors.affiliation: Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
authors.forename: Paul D
authors.initials: PD
authors.lastname: Fey
authors.affiliation: Department of Internal Medicine and Infectious Disease, University of Nebraska Medical Center, Omaha, USA.
authors.forename: Ziba
authors.initials: Z
authors.lastname: Jalali
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents; D017576:Daptomycin / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D015819:Substance Abuse, Intravenous / Q000150:complications
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin